Preferred Label : Samotolisib;
NCIt synonyms : 2H-Imidazo(4,5-C)quinolin-2-one, 1,3-Dihydro-8-(5-(1-hydroxy-1-methylethyl)-3-pyridinyl)-1-((2S)-2-methoxypropyl)-3-methyl-; WHO 10889;
NCIt related terms : PI3K/mTOR Inhibitor LY3023414;
NCIt definition : An orally bioavailable, small molecule inhibitor of certain class I phosphoinositide
3-kinase (PI3K) isoforms and mammalian target of rapamycin kinase (mTOR) in the PI3K/mTOR
signaling pathway, with potential antineoplastic activity. Samotolisib inhibits both
certain PI3K isoforms and mTOR in an ATP-competitive manner which may inhibit both
the PI3K/mTOR signaling pathway in and proliferation of tumor cells overexpressing
PI3K and/or mTOR. The PI3K/mTOR pathway is upregulated in a variety of tumor cells
and plays a key role in promoting cancer cell proliferation, and survival, motility
and resistance to chemotherapy and radiotherapy. mTOR, a serine/threonine kinase downstream
of PI3K, may also be activated in a PI3K-independent fashion; therefore, this agent
may be more potent than an agent that inhibits either PI3K or mTOR alone. In addition,
LY3023414 may inhibit DNA-dependent protein kinase (DNA-PK), thereby inhibiting the
ability of tumor cells to repair damaged DNA. DNA-PK is activated upon DNA damage
and plays a key role in repairing double-stranded DNA breaks.;
UNII : C88817F47Y;
InChIKey : ACCFLVVUVBJNGT-AWEZNQCLSA-N;
CAS number : 1386874-06-1;
Molecule name : LY-3023414; LY 3023414;
NCI Metathesaurus CUI : CL446628;
Origin ID : C121817;
UMLS CUI : C5203802;
Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_target
